Jane Street
CLDX icon

Jane Street’s Celldex Therapeutics CLDX Stock Holding History

Jane Street’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,200
Closed -$316K – 11245
2025
Q3 		$316K Buy
12,200
+1,200
+11% +$27.8K ﹤0.01% 8799
2025
Q2 		$224K Sell
11,000
-107,300
-91% -$2.09M ﹤0.01% 8365
2025
Q1 		$2.15M Sell
118,300
-87,400
-42% -$1.95M ﹤0.01% 4237
2024
Q4 		$5.2M Sell
205,700
-37,900
-16% -$1.03M ﹤0.01% 2604
2024
Q3 		$8.28M Sell
243,600
-24,700
-9% -$941K ﹤0.01% 2137
2024
Q2 		$9.93M Buy
268,300
+5,100
+2% +$192K ﹤0.01% 2057
2024
Q1 		$11M Buy
263,200
+9,800
+4% +$402K ﹤0.01% 1723
2023
Q4 		$10M Buy
253,400
+242,900
+2,313% +$7.14M ﹤0.01% 1950
2023
Q3 		$289K Sell
10,500
-2,900
-22% -$90.9K ﹤0.01% 7114
2023
Q2 		$455K Buy
+13,400
New +$452K ﹤0.01% 6456
2023
Q1 		– Sell
-84,400
Closed -$3.76M – 9120
2022
Q4 		$3.76M Sell
84,400
-600
-0.7% -$21.4K ﹤0.01% 2879
2022
Q3 		$2.39M Sell
85,000
-115,900
-58% -$3.55M ﹤0.01% 3881
2022
Q2 		$5.42M Buy
200,900
+164,600
+453% +$4.78M ﹤0.01% 2547
2022
Q1 		$1.24M Buy
36,300
+27,800
+327% +$889K ﹤0.01% 5693
2021
Q4 		$328K Sell
8,500
-6,000
-41% -$261K ﹤0.01% 8008
2021
Q3 		$783K Sell
14,500
-21,900
-60% -$1.03M ﹤0.01% 6409
2021
Q2 		$1.22M Sell
36,400
-6,000
-14% -$165K ﹤0.01% 5395
2021
Q1 		$873K Buy
42,400
+27,900
+192% +$641K ﹤0.01% 5715
2020
Q4 		$254K Buy
+14,500
New +$261K ﹤0.01% 6635
2020
Q3 		– Sell
-44,500
Closed -$579K – 7196
2020
Q2 		$579K Buy
+44,500
New +$197K ﹤0.01% 4846
2016
Q1 		– Sell
-6,860
Closed -$1.61M – 4097
2015
Q4 		$1.61M Buy
+6,860
New +$1.5M 0.01% 1265
2015
Q3 		– Sell
-587
Closed -$222K – 3614
2015
Q2 		$222K Sell
587
-426
-42% -$169K ﹤0.01% 3168
2015
Q1 		$424K Buy
+1,013
New +$362K ﹤0.01% 2204

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Jane Street's CLDX Position: Q1 2026 in Review

Jane Street opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 90,321 shares worth $2.86M. The stake represents ﹤0.01% of the portfolio and ranks #4431 among its holdings. This is a return to the name: Jane Street previously reported a position in CLDX as recently as Q2 2025.

Jane Street first reported a position in CLDX in Q2 2013 and has held it in 32 quarters since. The position peaked at $7.42M in Q1 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Jane Street held 90,321 shares of Celldex Therapeutics worth $2.86M as of Q1 2026.
  • Celldex Therapeutics was a new Jane Street position in Q1 2026.
  • Celldex Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4431 holding.
  • Jane Street first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 32 quarters since.
  • Jane Street's Celldex Therapeutics position peaked at $7.42M in Q1 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.